Impacts of COVID-19 pandemic on the collection and use of blood and blood components in Taiwan.

Impacts of COVID-19 pandemic on the collection and use of blood and blood components in Taiwan.

Publication date: Mar 27, 2024

The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted the supply and transfusion of blood components. This study aims to evaluate changes in blood collection and transfusions during the period following the nationwide Level 3 alert (May-July 2021). We retrieved usage data for red blood cells (RBC) from the Taiwan National Health Insurance (NHI) database 2019-2021. During the Level 3 alert period, approximately 85% of COVID-19 cases (11,455/13,624) were in Taipei. In Taipei, blood collection declined by 26. 34% and RBC transfusions decreased by 17. 14% compared to pre-pandemic levels. RBC usage decreased across all service types, with a significant decrease observed in hematology/oncology by 15. 62% (-483 patients, -2,425 units). In non-Taipei regions, blood collection declined by 12. 54%, rebounding around one month earlier than in Taipei. The decline in RBC transfusions occurred one month later than in Taipei, with a much lower magnitude (4. 57%). Strain on the blood supply occurred in May and June in both Taipei and non-Taipei regions. Among 7,532 hospitalized COVID-19 patients, approximately 6. 9% patients required a total of 1,873 RBC transfusions. The rapid increase in COVID-19 inpatients did not significantly increase the burden of blood demands. During the Level 3 alert, the most significant decline in both RBC collection and transfusions was observed in Taipei. In non-Taipei regions, the decrease in RBC use was only marginal. Notably, there was a significant decrease in RBC use in hematology/oncology in Taipei. This study supports transfusion specialists in seeking efficient ways to address similar future challenges.

Concepts Keywords
Coronavirus Coronavirus disease-2019
Efficient Level 3 alert
Hematology Red blood cells
June
Taiwan

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease IDO blood
disease VO efficient
disease MESH Long Covid
pathway KEGG Coronavirus disease

Original Article

(Visited 1 times, 1 visits today)